Response
| . | Overall, N . | RERs, n (%) . | CR after chemotherapy, n (%) . | CR after radiation, n (%) . |
|---|---|---|---|---|
| All patients | 216 | 132 (63) | 134 (64) | 180 (90) |
| Evaluable | 209 | 209 | 200 | |
| Intermediate risk | 53 | 35 (67) | 33 (66) | 44 (96) |
| Stage IB | 1 | 1 | 1 | 1 |
| Stage IIA LMA | 34 | 22 | 19 | 28 |
| Stage IIIA | 18 | 12 | 13 | 15 |
| High risk | 163 | 97 (61) | 101 (64) | 136 (88) |
| Stage IIB | 49 | 34 | 33 | 43 |
| Stage IIIB | 37 | 27 | 24 | 32 |
| Stage IVA | 26 | 13 | 16 | 21 |
| Stage IVB | 51 | 23 | 28 | 40 |
| “B” symptoms | ||||
| No | 78 | 46 (62) | 47 (65) | 62 (91) |
| Yes | 138 | 86 (63) | 87 (64) | 118 (89) |
| LMA | ||||
| Yes | 125 | 79 (64) | 75 (63) | 103 (90) |
| No | 79 | 47 (61) | 53 (70) | 67 (89) |
| Dexrazoxane | ||||
| Yes | 107 | 57 (56)* | 60 (60) | 87 (86) |
| No | 109 | 75 (69) | 74 (70) | 93 (94) |
| . | Overall, N . | RERs, n (%) . | CR after chemotherapy, n (%) . | CR after radiation, n (%) . |
|---|---|---|---|---|
| All patients | 216 | 132 (63) | 134 (64) | 180 (90) |
| Evaluable | 209 | 209 | 200 | |
| Intermediate risk | 53 | 35 (67) | 33 (66) | 44 (96) |
| Stage IB | 1 | 1 | 1 | 1 |
| Stage IIA LMA | 34 | 22 | 19 | 28 |
| Stage IIIA | 18 | 12 | 13 | 15 |
| High risk | 163 | 97 (61) | 101 (64) | 136 (88) |
| Stage IIB | 49 | 34 | 33 | 43 |
| Stage IIIB | 37 | 27 | 24 | 32 |
| Stage IVA | 26 | 13 | 16 | 21 |
| Stage IVB | 51 | 23 | 28 | 40 |
| “B” symptoms | ||||
| No | 78 | 46 (62) | 47 (65) | 62 (91) |
| Yes | 138 | 86 (63) | 87 (64) | 118 (89) |
| LMA | ||||
| Yes | 125 | 79 (64) | 75 (63) | 103 (90) |
| No | 79 | 47 (61) | 53 (70) | 67 (89) |
| Dexrazoxane | ||||
| Yes | 107 | 57 (56)* | 60 (60) | 87 (86) |
| No | 109 | 75 (69) | 74 (70) | 93 (94) |
Percentages were calculated excluding patients whose data were unknown. RER is defined by gallium negativity and 50% reduction in 2-dimensional tumor size after 3 cycles of chemotherapy. CR is defined by CT-based response of 70% or more at the end of chemotherapy and after radiation; those not achieving this anatomic response often had residual fibrosis rather than active disease.
P = .07 for difference in RERs in dexrazoxane vs no dexrazoxane.